ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Alexion partners with Complement Pharma on neurodegenerative therapy

by Ryan Cross
June 17, 2018 | APPEARED IN VOLUME 96, ISSUE 25

 

Alexion Pharmaceuticals is teaming up with Amsterdam-based Complement Pharma to test its antibody that inhibits an immune-system protein called C6, which forms pores in cells, causing them to lyse. C6 inhibition in animal models for nerve injury, traumatic brain injury, and Guillain-Barré syndrome suggests the therapy could be useful for many neurodegenerative conditions. Complement will receive up to $17 million in milestone payments as it tests the compound in a Phase I clinical trial. Alexion also has an option to acquire Complement.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment